• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.晚期乳腺癌中预测细胞毒性治疗反应的肿瘤生物学因素的多变量分析。
Br J Cancer. 1998 Sep;78(6):812-5. doi: 10.1038/bjc.1998.584.
2
Can expression of apoptosis genes, bcl-2 and bax, predict survival and responsiveness to chemotherapy in node-negative breast cancer patients?凋亡基因bcl-2和bax的表达能否预测淋巴结阴性乳腺癌患者的生存率及对化疗的反应?
J Surg Res. 2001 Aug;99(2):161-8. doi: 10.1006/jsre.2001.6084.
3
Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.拓扑异构酶IIα及其他预后因素对晚期乳腺癌表柔比星化疗的预测价值
Br J Cancer. 1998 Jun;77(12):2267-73. doi: 10.1038/bjc.1998.377.
4
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.在接受多柔比星和环磷酰胺序贯紫杉醇辅助化疗的III期乳腺癌患者中,bcl-2表达的预后意义
BMC Cancer. 2007 Apr 12;7:63. doi: 10.1186/1471-2407-7-63.
5
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.促凋亡基因BAX表达降低与转移性乳腺腺癌女性患者联合化疗反应率低及生存期短相关。
Cancer Res. 1995 Oct 1;55(19):4471-8.
6
Immunohistochemical expression of Bcl-2 protein in breast lesions: correlation with Bax, p53, Rb, C-erbB-2, EGFR and proliferation indices.Bcl-2蛋白在乳腺病变中的免疫组化表达:与Bax、p53、Rb、C-erbB-2、EGFR及增殖指数的相关性
Anticancer Res. 2000 Nov-Dec;20(6B):4221-5.
7
Immunofluorometric study of Bcl-2 and Bax expression in clinical fresh tumor samples from breast cancer patients.乳腺癌患者临床新鲜肿瘤样本中Bcl-2和Bax表达的免疫荧光测定研究
Anticancer Res. 2003 Jan-Feb;23(1B):565-8.
8
Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature.子宫内膜腺癌的免疫组织化学特征:61例研究及文献综述
Mod Pathol. 2000 Apr;13(4):379-88. doi: 10.1038/modpathol.3880062.
9
Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.乳腺癌中bcl-2、细胞凋亡、P53和HER-2/neu的多变量分析:短期随访
Anticancer Res. 2002 Jul-Aug;22(4):2493-9.
10
The predictive value of bcl-2, bax, bcl-xL, bag-1, fas, and fasL for chemotherapy response in advanced breast cancer.bcl-2、bax、bcl-xL、bag-1、fas和fasL对晚期乳腺癌化疗反应的预测价值。
Clin Cancer Res. 2002 Mar;8(3):811-6.

引用本文的文献

1
The essential role of evasion from cell death in cancer.逃避细胞死亡在癌症中的重要作用。
Adv Cancer Res. 2011;111:39-96. doi: 10.1016/B978-0-12-385524-4.00002-7.
2
Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials.雌激素受体表达与多西他赛疗效在转移性乳腺癌患者中的相关性:四项随机试验的汇总分析。
Oncologist. 2010;15(5):476-83. doi: 10.1634/theoncologist.2009-0150. Epub 2010 Apr 26.
3
Improvement of the clinical applicability of the Genomic Grade Index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues.通过对冷冻组织以及福尔马林固定石蜡包埋组织进行定量逆转录聚合酶链反应(qRT-PCR)检测,提高基因组分级指数的临床适用性。
BMC Genomics. 2009 Sep 10;10:424. doi: 10.1186/1471-2164-10-424.
4
Apoptosis and cancer: the genesis of a research field.细胞凋亡与癌症:一个研究领域的起源
Nat Rev Cancer. 2009 Jul;9(7):501-7. doi: 10.1038/nrc2663.
5
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.荟萃分析证实BCL2是乳腺癌的一个独立预后标志物。
BMC Cancer. 2008 May 29;8:153. doi: 10.1186/1471-2407-8-153.
6
Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer.局部晚期乳腺癌新辅助蒽环类化疗反应的临床和病理预测因素
Med Oncol. 2006;23(2):171-83. doi: 10.1385/MO:23:2:171.
7
Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a mexican population of locally advanced breast cancer patients.在墨西哥局部晚期乳腺癌患者群体中,Her-2/neu表达作为基于蒽环类化疗反应的预测因子。
Med Oncol. 2005;22(1):23-8. doi: 10.1385/MO:22:1:023.
8
Bax regulates c-Myc-induced mammary tumour apoptosis but not proliferation in MMTV-c-myc transgenic mice.在MMTV-c-myc转基因小鼠中,Bax调节c-Myc诱导的乳腺肿瘤细胞凋亡,但不调节其增殖。
Br J Cancer. 2004 Oct 4;91(7):1372-9. doi: 10.1038/sj.bjc.6602137.
9
Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.拓扑异构酶IIα的扩增和缺失与ErbB-2扩增相关,并影响乳腺癌对拓扑异构酶II抑制剂阿霉素的敏感性。
Am J Pathol. 2000 Mar;156(3):839-47. doi: 10.1016/s0002-9440(10)64952-8.
10
Number of apoptotic cells as a prognostic marker in invasive breast cancer.凋亡细胞数量作为浸润性乳腺癌的预后标志物
Br J Cancer. 2000 Jan;82(2):368-73. doi: 10.1054/bjoc.1999.0928.

本文引用的文献

1
Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer.c-erbB-2、p53、组织蛋白酶D及原发性肿瘤组织学在转移性乳腺癌中的预测价值
Br J Cancer. 1997;76(7):917-22. doi: 10.1038/bjc.1997.484.
2
Predictive factors for response to cytotoxic treatment in advanced breast cancer: a review.晚期乳腺癌细胞毒性治疗反应的预测因素:综述
Acta Oncol. 1996;35 Suppl 5:84-90. doi: 10.3109/02841869609083978.
3
Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration.
J Clin Oncol. 1993 Mar;11(3):467-73. doi: 10.1200/JCO.1993.11.3.467.
4
Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes.正常和肿瘤性淋巴结中Mcl-1和Bcl-2蛋白的免疫组织化学分析
Am J Pathol. 1994 Sep;145(3):515-25.
5
Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2.免疫组织化学法检测Bax(一种Bcl - 2的主要抑制剂)在体内的分布情况。
Am J Pathol. 1994 Dec;145(6):1323-36.
6
Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?原发性肿瘤中的DNA倍体和S期分数能否预测转移性乳腺癌对化疗的反应?
Br J Cancer. 1995 May;71(5):1029-32. doi: 10.1038/bjc.1995.198.
7
Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma.促凋亡基因BAX表达降低与转移性乳腺腺癌女性患者联合化疗反应率低及生存期短相关。
Cancer Res. 1995 Oct 1;55(19):4471-8.
8
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy.
J Natl Cancer Inst. 1989 Sep 20;81(18):1383-7. doi: 10.1093/jnci/81.18.1383.
9
Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer.P-糖蛋白表达的免疫组织化学分析与局部晚期乳腺癌的化疗耐药性相关。
Hum Pathol. 1990 Aug;21(8):787-91. doi: 10.1016/0046-8177(90)90046-8.
10
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up.乳腺癌的病理预后因素。I. 乳腺癌组织学分级的价值:一项长期随访大型研究的经验
Histopathology. 1991 Nov;19(5):403-10. doi: 10.1111/j.1365-2559.1991.tb00229.x.

晚期乳腺癌中预测细胞毒性治疗反应的肿瘤生物学因素的多变量分析。

A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer.

作者信息

Sjöström J, Krajewski S, Franssila K, Niskanen E, Wasenius V M, Nordling S, Reed J C, Blomqvist C

机构信息

Department of Oncology, Helsinki University Central Hospital, Finland.

出版信息

Br J Cancer. 1998 Sep;78(6):812-5. doi: 10.1038/bjc.1998.584.

DOI:10.1038/bjc.1998.584
PMID:9743306
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2062970/
Abstract

The study was designed to identify factors that could predict response to chemotherapy in breast cancer. A total of 173 patients with measurable or evaluable metastatic breast cancer were enrolled in a randomized trial between November 1987 and January 1991 to receive a monthly dose of 5-fluorouracil (500 mg m(-2)), epirubicin (60 mg m(-2)) and cyclophosphamide (500 mg m(-2)) either administered in four weekly doses or in an every-4-week dose as first-line cytotoxic treatment. In 103 evaluable patients we performed a multivariate analysis of the tumour biological factors, i.e. histological grade, oestrogen receptor (ER), progesterone receptor (PR), S-phase fraction (SPF), ploidy, p53, c-erbB-2, Bcl-2 and Bax expression, which showed significance in the univariate analysis according to treatment response, time to progression (TTP) or overall survival (OS). In the univariate analysis only SPF, grade and the proapoptotic protein Bax correlated with the response to cytotoxic treatment. In the multivariate analysis SPF had the strongest correlation, followed by grade and Bax. In the univariate analysis grade, PR, Bax and Bcl-2 correlated significantly with TTP, whereas in the multivariate analysis only PR showed a statistically significant correlation. In the univariate analysis PR and Bax correlated with OS and both retained its significance in the multivariate analysis. The factors that correlated significantly with the response to cytotoxic treatment in the univariate analysis, i.e. grade, SPF and Bax, seemed to predict independently the response to treatment in the multivariate analysis also. TTP and OS could be predicted partly by the same factors, although the association was quite weak. More studies and new tumour biological factors are needed to identify the group of breast cancer patients who get the most benefit from chemotherapy.

摘要

该研究旨在确定可预测乳腺癌化疗反应的因素。1987年11月至1991年1月期间,共有173例可测量或可评估的转移性乳腺癌患者参加了一项随机试验,接受每月剂量的5-氟尿嘧啶(500 mg m(-2))、表柔比星(60 mg m(-2))和环磷酰胺(500 mg m(-2)),以四周一次剂量或每4周一次剂量给药,作为一线细胞毒性治疗。在103例可评估患者中,我们对肿瘤生物学因素进行了多变量分析,即组织学分级、雌激素受体(ER)、孕激素受体(PR)、S期分数(SPF)、倍性、p53、c-erbB-2、Bcl-2和Bax表达,这些因素在单变量分析中根据治疗反应、疾病进展时间(TTP)或总生存期(OS)显示出显著性。在单变量分析中,只有SPF、分级和促凋亡蛋白Bax与细胞毒性治疗反应相关。在多变量分析中,SPF的相关性最强,其次是分级和Bax。在单变量分析中,分级、PR、Bax和Bcl-2与TTP显著相关,而在多变量分析中只有PR显示出统计学上的显著相关性。在单变量分析中,PR和Bax与OS相关,且两者在多变量分析中均保持其显著性。在单变量分析中与细胞毒性治疗反应显著相关的因素,即分级、SPF和Bax,在多变量分析中似乎也能独立预测治疗反应。TTP和OS可部分由相同因素预测,尽管这种关联相当微弱。需要更多的研究和新的肿瘤生物学因素来确定从化疗中获益最大的乳腺癌患者群体。